These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35241461)

  • 41. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study.
    Campos NG; Lince-Deroche N; Chibwesha CJ; Firnhaber C; Smith JS; Michelow P; Meyer-Rath G; Jamieson L; Jordaan S; Sharma M; Regan C; Sy S; Liu G; Tsu V; Jeronimo J; Kim JJ
    J Acquir Immune Defic Syndr; 2018 Oct; 79(2):195-205. PubMed ID: 29916959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review.
    Mezei AK; Armstrong HL; Pedersen HN; Campos NG; Mitchell SM; Sekikubo M; Byamugisha JK; Kim JJ; Bryan S; Ogilvie GS
    Int J Cancer; 2017 Aug; 141(3):437-446. PubMed ID: 28297074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC: a systematic review and meta-analysis.
    Mekuria SF; Timmermans S; Borgfeldt C; Jerkeman M; Johansson P; Linde DS
    Syst Rev; 2023 Jun; 12(1):103. PubMed ID: 37349822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation.
    Huntington S; Puri Sudhir K; Schneider V; Sargent A; Turner K; Crosbie EJ; Adams EJ
    BMJ Open; 2023 Jun; 13(6):e068940. PubMed ID: 37280031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of a two-stage strategy with HPV testing followed by visual inspection with acetic acid for cervical cancer screening in a low-income setting.
    Tebeu PM; Fokom-Domgue J; Crofts V; Flahaut E; Catarino R; Untiet S; Vassilakos P; Petignat P
    Int J Cancer; 2015 Mar; 136(6):E743-50. PubMed ID: 25284599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
    Campos NG; Castle PE; Wright TC; Kim JJ
    Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
    Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
    Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
    Sharma M; Seoud M; Kim JJ
    Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for cancer in low- and middle-income countries.
    Sankaranarayanan R
    Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
    Okeah BO; Ridyard CH
    Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
    Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health economic evaluation of primary human papillomavirus screening in urban populations in China.
    Keane A; Shi JF; Simms KT; Liu YJ; Lew JB; Mazariego C; Yuill S; Wu RF; Liu ZH; Zhao FH; Jeronimo J; Canfell K; Qiao YL
    Cancer Epidemiol; 2021 Feb; 70():101861. PubMed ID: 33310688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.
    Bruni L; Serrano B; Roura E; Alemany L; Cowan M; Herrero R; Poljak M; Murillo R; Broutet N; Riley LM; de Sanjose S
    Lancet Glob Health; 2022 Aug; 10(8):e1115-e1127. PubMed ID: 35839811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
    Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.